Lancet Diabetes & Endocrinology

Article	Citations
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale	1029
World Health Assembly ratifies first global diabetes targets	722
Mark Atkinson: bringing two worlds together	623
What's preventing us from curbing the obesity crisis?	609
Direct-to-consumer services: improving access to care for people with diabetes and obesity	449
Better testing and labelling of drugs for people with obesity	448
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98	446
Type 1 diabetes screening: need for ethical, equity, and health systems perspective	441
Artificial intelligence and diabetes: time for action and caution	403
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?	382
South Africa to produce insulin for Africa in 2024	376
Anand Hardikar: a scientific nomad searching for the truth	375
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2	344
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial	284
A framework for improving diabetes care in humanitarian emergencies	229
Implications of technology guidelines for low-income and middle-income countries	227
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p	218
Reassessing driving safety in diabetes	203
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality	198
Obesity in people living with type 1 diabetes	196
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice	183
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions	178
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial	164
Nutritional intake and bone health	163
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial	157

Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials	152
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity	151
Jennifer Manne-Goehler: at the crossroads of pandemics	143
The uncomfortable truth about kidney disease in type 1 diabetes	141
A roadmap for integrating mental health and diabetes services	141
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials	140
Challenging diabetes stigma starts and ends with all of us	139
The changing character of diabetes complications	130
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses	130
Dapagliflozin in patients with COVID-19: truth or dare	127
Putting wellbeing at the core of diabetes care	127
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study	126
Glycaemic index as part of the diabetes prevention strategy	123
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing	121
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin	120
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply	118
Lebanon: insulin out of reach after subsidies lifted	112
Rising diabetes diagnosis in long COVID	110
Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss	110
The promise and hope of GLP-1 receptor agonists	108
What does renal failure teach us about our National Health System?	102
Correction to Lancet Diabetes Endocrinol 2025; published online April 7. https://doi.org/10.1016/S2213-8587(25)00087-7	101
The role of nurses in diabetes care: challenges and opportunities	100
Explaining the high rate of progression from prediabetes to type 2 diabetes in China	98
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study	96
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history	94
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020	91
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis	90
Healthy weight for the next generation's health in China	89
Childhood obesity: a growing pandemic	83
Women in diabetes research: stepping towards equity	81
Is it time to re-assess the development of thyroid function reference ranges?	76
Blood pressure control according to type 2 diabetes status	75
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–17	73
Correction to Lancet Diabetes Endocrinol 2023; 11: 402–13	73
Homing in on the causes of male infertility	72
Hypothalamic obesity: from basic mechanisms to clinical perspectives	72
Diabetes: knowing your risk matters	71
Correction to Lancet Diabetes Endocrinol 2022; 10: 481–83	71
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction	69
A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international	67
Improving HbA1c levels with advanced hybrid closed-loop therapy	67
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international	66
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors	66
Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019	66
Understanding the mechanism of prediabetes remission in young people	66
Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study	66
Male hypogonadism: pathogenesis, diagnosis, and management	65
Glucagon, from past to present: a century of intensive research and controversies	65
CONCEPTT to care: the science of implementation in diabetes care	65

Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants	64
Bothersome vasomotor symptoms: a potential early clinical marker of perimenopause?	64
Gender equality: timely and timeless	64
On the occasion of International Women's Day	63
SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes	63
TB Joshua and his megachurch: fake medical miracles and abuse in Nigeria	62
Central diabetes insipidus from a patient's perspective	62
Chronicling insulin from discovery to crisis	61
Corrections to Lancet Diabetes Endocrinol 2022; 10: 120–28	60
Vitamin D and fractures	59
Improving support for university students with type 1 diabetes	59
Teplizumab approval for type 1 diabetes in the USA	58
Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data	58
Efficacy and safety of automated insulin delivery in children aged 2–6 years (LENNY): an open-label, multicentre, randomised, crossover trial	57
Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-b	57
Mendelian randomisation and vitamin D: the importance of model assumptions – Authors' reply	56
GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study	55
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat	54
Screening type 1 diabetes and celiac disease by law	53
Health disparities in transgender people	53
Embracing community sport to promote global health	53
Management of menopause: a view towards prevention	53
Diagnosing diabetes in African populations: a twist in the tale	52
Methodological considerations in D-health cancer mortality results – Authors' reply	52
How do clinicians integrate oral octreotide into their treatment plan for acromegaly?	51
Steps to redressing an imbalance: GLP-1 analogues for obesity in east Asia	51
Correction to Lancet Diabetes Endocrinol 2022; 10: 668–80	51
Correction to Lancet Diabetes Endocrinol 2024; 12: 233–46	50
Young adult-onset type 2 diabetes heralds a poor prognosis	50
Insulin regimens during type 1 diabetes pregnancy	49
Automated insulin delivery postpartum: insights from the AiDAPT study extension	48
Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study	48
Decision making in differences of sex development/intersex care in the USA: bridging advocacy and family-centred care	48
More options for young children with type 1 diabetes	48
Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 nati	48
Technology for type 1 diabetes: what impact will it have?	48
Is the impact of add on heart failure therapy influenced by background therapy?	47
Blood glucose targets in the critically ill: is one size fits all still appropriate?	47
Viswanathan Mohan: a dynasty of diabetology	47
Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2023	46
RETRACTED: Targeting of vitamin D supplementation to individuals with deficiency	46
Creating diabetes guidelines for the individual not just the illness	45
MarÍa José Redondo: rethinking type 1 diabetes	45
Explaining the high rate of progression from prediabetes to type 2 diabetes in China – Authors' reply	44
Enhancing global access to diabetes medicines: policy lessons from the HIV response	43
An inclusive approach to people with disabilities in diabetes care and education	43
ORION-3: delivering lipid lowering treatment for longer	43
Impact of higher BMI on cardiometabolic risk: does height matter?	42
How clinically relevant is statin-induced diabetes?	41
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	41
Associations between BMI and hospital resource use in patients hospitalised for COVID-19 in England: a community-based cohort study	41
Disparities in fragility fracture and osteoporosis care in Africa	41
Addressing health and demographic challenges in Japan's ageing society	40
Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind,	39
Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial	38
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial	38
Type 1 diabetes in diverse ancestries and the use of genetic risk scores	38
Redefining obesity: advancing care for better lives	38
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial	38
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial	38
Burden of diabetes and hyperglycaemia in adults in the Americas, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	37
Risks and burdens of incident diabetes in long COVID: a cohort study	37
What's in a decade?	36
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials	36
Data processing in the DMagic cluster randomised controlled trial	35
Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial	35
Gender disparities in publishing: from words to actions	35
From prominent corneal nerves to multiple endocrine neoplasia type 2B	34
Perfluoroalkyl and polyfluoroalkyl substances: the price of forever chemicals	34
The growing global burden of thyroid cancer overdiagnosis	34
Correction to Lancet Diabetes Endocrinol 2022; 10: 741–60	33
Disease modifying therapies in diabetes and endocrinology	33
Setmelanotide: new promise for the treatment of hypothalamic obesity?	32
Mendelian randomisation and vitamin D: the importance of model assumptions	32
Iodine deficiency in Europe: vigilance and action required	31
Diabetes and the WHO Model List of Essential Medicines	31
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials	31
Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple	30
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study	30
The potential role for artificial intelligence in fracture risk prediction	30

Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial	30
Osteoporosis in men	29
Sleep: a neglected public health issue	29
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel	29
Incretins and the cardiovascular system: bridging digestion with metabolism	28
The double burden of poor diets	28
Sex differences in familial hypercholesterolaemia	28
Prevention of diabetes mortality at ages younger than 25 years: access to medications and high-quality health care	27
Long-term population-based trends in the incidence of cardiovascular disease in individuals with type 1 diabetes from Finland: a retrospective, nationwide, cohort study	27
Contribution of heterozygous PCSK1 variants to obesity and implications for precision medicine: a case-control study	27
Maternal thyroid hypofunction and gestational diabetes risk	27
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial	27
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicent	26
Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis	26
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial	25
Revisiting osteoporosis guidelines	25
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes	24
Identifying adults at high-risk for change in weight and BMI in England: a longitudinal, large-scale, population-based cohort study using electronic health records	24
Lessons to learn from the 2024 NICE guideline on adrenal insufficiency	23
The power of resilience	23
Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes	23
PFAS: here today—here tomorrow	23
From research to policy: still a long way to go	23
Reversibility of congenital hypogonadotropic hypogonadism: lessons from a rare disease	22
Achieving replicable subphenotypes of adult-onset diabetes – Authors' reply	22
SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?	22
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	22
Sexual dimorphism in COVID-19: potential clinical and public health implications	22
Bariatric surgery in children with obesity and type 2 diabetes	22
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase	21
The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review	21
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement	21
Endocrine health in survivors of adult-onset cancer	21
Association between maternal diabetes and neurodevelopmental outcomes in children: a systematic review and meta-analysis of 202 observational studies comprising 56·1 million pregnancies	21
A global plastics treaty to protect endocrine health	21
Statins for Graves' orbitopathy: a new tool for prevention and treatment?	20
Sugar, sugary drinks, and health: has the evidence achieved the sweet spot for policy action?	20
Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues?	20
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes	20
Good news for patients with adrenocortical carcinoma from the ADIUVO trial	19
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality – Authors' reply	18
A call for increased involvement of people with obesity and neurodiversity in policy, research, and practice	18
Analysis of cluster randomised trials as if they were individually randomised – Authors' reply	18
The voices of lived experience in diabetes and endocrinology	18
Correction to Lancet Diabetes Endocrinol 2023; 11: 905–14	17
Mendelian randomisation at 20 years: how can it avoid hubris, while achieving more?	17
Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from th	17
COVID-19 targets human adrenal glands	17
Does tirzepatide treatment improve skeletal muscle composition?	17
Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: insights from three prospective cohort studies	17
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial	17
Trends in the incidence of young-adult-onset diabetes by diabetes type: a multi-national population-based study from an international diabetes consortium	17
Halving heart failure outcomes by finerenone-mediated type 2 diabetes prevention	16
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial	16
The ISPAD Clinical Practice Consensus Guidelines 2022: how far we have come and the distance still to go	16
Predicting and preventing heart failure in type 2 diabetes	16
Denosumab in the treatment of osteoporosis associated with chronic kidney disease	15
Correction to Lancet Diabetes Endocrinol 2023; 11: 567–77	15
Endpoints for clinical trials in type 1 diabetes drug development	15
Diabetes educators: rewriting the narrative	15
Is autonomous cortisol secretion sexually dimorphic?	15
The evidence for achondroplasia in 1st century AD Italy	15
Food additive emulsifiers and risk of type 2 diabetes	15
Type 1 diabetes: one size does not fit all	15
Migrant health: a global responsibility	15
The obesity drug craze in Brazil	15
Access to insulin and diabetes care in the Philippines	15